Home Cart 0 Sign in  
X

[ CAS No. 3449-48-7 ] {[proInfo.proName]}

,{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]}
3d Animation Molecule Structure of 3449-48-7
Chemical Structure| 3449-48-7
Chemical Structure| 3449-48-7
Structure of 3449-48-7 * Storage: {[proInfo.prStorage]}
Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Quality Control of [ 3449-48-7 ]

Related Doc. of [ 3449-48-7 ]

Alternatived Products of [ 3449-48-7 ]

Product Details of [ 3449-48-7 ]

CAS No. :3449-48-7 MDL No. :MFCD00220361
Formula : C13H13NO Boiling Point : -
Linear Structure Formula :- InChI Key :ITWUGZSJDMBOPH-UHFFFAOYSA-N
M.W : 199.25 Pubchem ID :607984
Synonyms :

Calculated chemistry of [ 3449-48-7 ]

Physicochemical Properties

Num. heavy atoms : 15
Num. arom. heavy atoms : 9
Fraction Csp3 : 0.31
Num. rotatable bonds : 0
Num. H-bond acceptors : 1.0
Num. H-bond donors : 1.0
Molar Refractivity : 61.12
TPSA : 32.86 Ų

Pharmacokinetics

GI absorption : High
BBB permeant : Yes
P-gp substrate : Yes
CYP1A2 inhibitor : Yes
CYP2C19 inhibitor : Yes
CYP2C9 inhibitor : No
CYP2D6 inhibitor : Yes
CYP3A4 inhibitor : No
Log Kp (skin permeation) : -5.49 cm/s

Lipophilicity

Log Po/w (iLOGP) : 2.05
Log Po/w (XLOGP3) : 2.85
Log Po/w (WLOGP) : 3.0
Log Po/w (MLOGP) : 2.03
Log Po/w (SILICOS-IT) : 4.07
Consensus Log Po/w : 2.8

Druglikeness

Lipinski : 0.0
Ghose : None
Veber : 0.0
Egan : 0.0
Muegge : 1.0
Bioavailability Score : 0.55

Water Solubility

Log S (ESOL) : -3.31
Solubility : 0.0965 mg/ml ; 0.000484 mol/l
Class : Soluble
Log S (Ali) : -3.2
Solubility : 0.126 mg/ml ; 0.000633 mol/l
Class : Soluble
Log S (SILICOS-IT) : -4.67
Solubility : 0.00423 mg/ml ; 0.0000212 mol/l
Class : Moderately soluble

Medicinal Chemistry

PAINS : 0.0 alert
Brenk : 0.0 alert
Leadlikeness : 1.0
Synthetic accessibility : 2.04

Safety of [ 3449-48-7 ]

Signal Word:Warning Class:N/A
Precautionary Statements:P261-P305+P351+P338 UN#:N/A
Hazard Statements:H302-H315-H319-H335 Packing Group:N/A
GHS Pictogram:

Application In Synthesis of [ 3449-48-7 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Upstream synthesis route of [ 3449-48-7 ]
  • Downstream synthetic route of [ 3449-48-7 ]

[ 3449-48-7 ] Synthesis Path-Upstream   1~12

  • 1
  • [ 637-60-5 ]
  • [ 765-87-7 ]
  • [ 3449-48-7 ]
YieldReaction ConditionsOperation in experiment
62% With hydrogenchloride; acetic acid In methanol at 60℃; Inert atmosphere To a solution of 1,2-cyclohexanedione (2243 mg, 20 mmol) and concentrated hydrochloric acid (13 mL) in acetic acid (40 mL), p-tolylhydrazine hydrochloride (1586 mg, 10 mmol) in methanol (25 mL) was added dropwise slowly over 10 min.
After the addition, the resulting mixture was heated to 60 °C, and stirred overnight.
The solvent was evaporated, and the residue was pH adjusted to weak alkaline with saturated NaHCO3.
The mixture was extracted with AcOEt (3 * 20 mL).
The combined organic extract was washed with brine, dried over anhydrous Na2SO4, and concentrated.
The residue was purified by silica gel chromatography (petroleum ether/AcOEt, 12/1 v/v) to give intermediate 7 (1235 mg, 62percent) as a brown powder.
The mixture of intermediate 7 (102 mg, 0.5 mmol), 4-phenylbutylamine (0.12 mL, 0.8 mmol) and catalytic p-TsOH in toluene (10 mL) was refluxed at 140 °C for 16 h with a Dean-Stark trap in place.
The solvent was evaporated and the residue was dissolved in methanol. NaBH4 (177 mg) was then added at 0 °C.
The solution was heated to 80 °C until TLC indicated the reaction was complete.
The reaction was quenched with water and concentrated.
Subsequently, the mixture was extracted with AcOEt twice and the combined organic layers were dried over anhydrous Na2SO4.
After evaporation of the solvent, the resulting residue was purified by column chromatography on silica gel (petroleum ether/AcOEt, 4/1 v/v) to give compound 5 (123 mg, Yield: 72percent).1H NMR (300MHz, CDCl3) δ 8.23 (s, 1H), 7.33–7.27 (m, 2H), 7.26–7.23 (m, 1H), 7.23–7.11 (m, 4H), 6.99–6.92 (m, 1H), 3.97–3.85 (m, 1H), 2.89–2.77 (m, 1H), 2.71–2.63 (m, 4H), 2.63–2.59 (m, 1H), 2.44 (s, 3H), 2.28–2.14 (m, 1H), 2.08–1.95 (m, 1H), 1.83–1.65 (m, 4H), 1.63–1.48 (m, 4H). 13C NMR (125MHz, DMSO‑d6) δ 142.28, 136.74, 134.21, 128.29, 128.18, 127.10, 126.27, 125.57, 121.96, 117.38, 110.68, 108.76, 51.61, 46.07, 35.22, 29.72, 29.34, 28.92, 21.27, 20.89, 20.76. HR MS (ESI): calcd for C23H29N2 [M+ H]+; 333.2331; found 333.2328.
Reference: [1] European Journal of Medicinal Chemistry, 2019, p. 203 - 211
[2] New Journal of Chemistry, 2009, vol. 33, # 4, p. 760 - 768
[3] European Journal of Medicinal Chemistry, 2011, vol. 46, # 11, p. 5675 - 5679
  • 2
  • [ 177352-49-7 ]
  • [ 3449-48-7 ]
Reference: [1] Organic Letters, 2013, vol. 15, # 22, p. 5698 - 5701
  • 3
  • [ 2257-17-2 ]
  • [ 3449-48-7 ]
Reference: [1] Indian Journal of Chemistry - Section B Organic and Medicinal Chemistry, 2011, vol. 50, # 2, p. 201 - 206
[2] Journal of the Indian Chemical Society, 1927, vol. 4, p. 484[3] Chem. Zentralbl., 1928, vol. 99, # I, p. 511
[4] Heterocycles, 1999, vol. 51, # 9, p. 2163 - 2169
[5] Journal of Chemical and Engineering Data, 2006, vol. 51, # 4, p. 1306 - 1309
[6] Bioorganic and Medicinal Chemistry Letters, 2009, vol. 19, # 13, p. 3489 - 3492
[7] Journal of Heterocyclic Chemistry, 2011, vol. 48, # 2, p. 331 - 338
  • 4
  • [ 762-42-5 ]
  • [ 3449-48-7 ]
  • [ 1293289-06-1 ]
Reference: [1] Tetrahedron Letters, 2011, vol. 52, # 14, p. 1649 - 1652
[2] Tetrahedron Letters, 2011, vol. 52, # 14, p. 1649 - 1652
  • 5
  • [ 637-60-5 ]
  • [ 6946-05-0 ]
  • [ 3449-48-7 ]
Reference: [1] Synthetic Communications, 2009, vol. 39, # 6, p. 1120 - 1127
  • 6
  • [ 39695-64-2 ]
  • [ 106-49-0 ]
  • [ 3449-48-7 ]
Reference: [1] Patent: US2009/156621, 2009, A1,
[2] Patent: US2009/170906, 2009, A1,
[3] Patent: US2009/170923, 2009, A1,
  • 7
  • [ 2257-17-2 ]
  • [ 3449-48-7 ]
Reference: [1] Journal of Heterocyclic Chemistry, 1990, vol. 27, # 7, p. 1947 - 1951
  • 8
  • [ 2028-84-4 ]
  • [ 823-45-0 ]
  • [ 3449-48-7 ]
Reference: [1] Journal of Heterocyclic Chemistry, 2011, vol. 48, # 2, p. 331 - 338
  • 9
  • [ 106-49-0 ]
  • [ 23740-64-9 ]
  • [ 3449-48-7 ]
Reference: [1] Tetrahedron, 2014, vol. 70, # 17, p. 2753 - 2760
  • 10
  • [ 533-60-8 ]
  • [ 539-44-6 ]
  • [ 3449-48-7 ]
Reference: [1] Journal of the Chemical Society, 1950, p. 1328,1330
  • 11
  • [ 1093413-51-4 ]
  • [ 3449-48-7 ]
  • [ 73910-76-6 ]
Reference: [1] Journal of Chemical Research, 2007, # 11, p. 653 - 656
  • 12
  • [ 64-19-7 ]
  • [ 2257-17-2 ]
  • [ 3449-48-7 ]
Reference: [1] Journal of the Indian Chemical Society, 1927, vol. 4, p. 484[2] Chem. Zentralbl., 1928, vol. 99, # I, p. 511
Same Skeleton Products
Historical Records

Related Functional Groups of
[ 3449-48-7 ]

Ketones

Chemical Structure| 15128-52-6

[ 15128-52-6 ]

2,3-Dihydro-1H-carbazol-4(9H)-one

Similarity: 0.91

Chemical Structure| 4264-35-1

[ 4264-35-1 ]

1-(1H-Indol-2-yl)ethanone

Similarity: 0.85

Chemical Structure| 40522-46-1

[ 40522-46-1 ]

2-Heptylquinolin-4(1H)-one

Similarity: 0.84

Chemical Structure| 113961-88-9

[ 113961-88-9 ]

1-(1,2,3,4-Tetrahydroquinolin-6-yl)ethanone

Similarity: 0.84

Chemical Structure| 578-95-0

[ 578-95-0 ]

Acridin-9(10H)-one

Similarity: 0.83

Related Parent Nucleus of
[ 3449-48-7 ]

Other Aromatic Heterocycles

Chemical Structure| 15128-52-6

[ 15128-52-6 ]

2,3-Dihydro-1H-carbazol-4(9H)-one

Similarity: 0.91

Chemical Structure| 578-95-0

[ 578-95-0 ]

Acridin-9(10H)-one

Similarity: 0.83

Chemical Structure| 13754-86-4

[ 13754-86-4 ]

6,7-Dihydro-1H-indol-4(5H)-one

Similarity: 0.82

Chemical Structure| 1127-74-8

[ 1127-74-8 ]

1,2,3,4-Tetrahydrobenzo[b]azepin-5-one

Similarity: 0.81

Chemical Structure| 21737-58-6

[ 21737-58-6 ]

5H-Dibenzo[b,f]azepin-10(11H)-one

Similarity: 0.81